Pneumonia caused by herpesviruses in recipients of hematopoietic cell transplants

Seminars in Respiratory Infections

Volumn 17, Issue 2, 2002, Pages 121-129

  Taplitz, Randy A ^a   Jordan, M Colin ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INTERFERON; PENCICLOVIR; VALACICLOVIR; VALGANCICLOVIR; VIDARABINE;

CLINICAL FEATURE; CLINICAL TRIAL; CROSS RESISTANCE; CYTOMEGALOVIRUS; DISEASE COURSE; DRUG CHOICE; DRUG INDICATION; DRUG SENSITIVITY; EPSTEIN BARR VIRUS; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX VIRUS; HERPES VIRUS; HUMAN; INFECTION PREVENTION; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STRAIN DIFFERENCE; SURVIVAL RATE; TREATMENT OUTCOME; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS STRAIN;

CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES ZOSTER; HERPESVIRIDAE INFECTIONS; HUMANS; PNEUMONIA, VIRAL;

EID: 0036082122     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2002.33447     Document Type: Review

References (73)

1. Infection in the bone marrow transplant recipient
2. Analysis of late infections after human bone marrow transplantation: Role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease
3. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
4. Late complications of allogeneic and autologous marrow transplantation
5. T and B cell deficiencies in patients with chronic graft-versus-host disease after HLA-identical marrow transplantation
6. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten years' experience
7. Respiratory virus infections after marrow transplant: The Fred Hutchinson Cancer Research Center experience
8. Herpesviridae
9. Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution
10. Activity of 9-[2-hydroxy-1-(hydroxy-methyl)ethoxymethyl] guanine in the treatment of cytomegalo-virus pneumonia
11. Ganciclovir therapy for cytomegalo-virus infections in recipients of bone marrow transplants and other immunosuppressed patients
12. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
13. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy
14. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients
15. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation
16. Laboratory diagnosis of viral infections of the lung
17. Cytomegalovirus antigenemia
18. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients
19. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation
20. High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV
21. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications
22. Acyclovir for prevention of cyto-megalovirus infection and disease after allogeneic marrow transplantation
23. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
24. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
25. A randomised trial comparing cyto-megalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients
26. Fiberoptic bronchoscopy in allogeneic bone marrow transplantation: Findings in the era of serum cytomegalovirus antigen surveillance
27. Qualitative plasma PCR assay (AMPLICOR CMV Test) versus pp 65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation
28. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients
29. Prophylaxis against herpesvirus infections in transplant recipients
30. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
31. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
32. Valganciclovir
33. Efficacy of immune globulin in preventing complications of bone marrow transplantation: A meta-analysis
34. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation
35. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
36. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and highdose intravenous immune globulin
37. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients
38. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group
39. Guidelines of preventing opportunistic infections among hematopoietic stem cell transplant recipients
40. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients
41. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
42. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients
43. Herpes simplex virus pneumonia: Clinical, virologic, and pathologic features in 20 patients
44. Late-onset herpes simplex virus-associated interstitial pneumonia after allogeneic bone marrow transplantation
45. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204)
46. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: Results of a multicenter, acyclovir-controlled trial
47. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation
48. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: Risk factors and prognostic significance
49. Resistant herpes simplex virus type I infection: An emerging concern after allogeneic stem cell transplantation
50. Infection with varicella-zoster virus after marrow transplantation
51. Varicella-zoster infection after allogeneic bone marrow transplantation: Incidence, risk factors and prevention with low-dose aciclovir and ganciclovir
52. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation
53. Detection of herpes viruses in clinical samples using real-time PCR
54. Anti-infective therapy for viral pneumonia
55. Acyclovir prevents dissemination of varicella in immunocompromised children
56. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients
57. The role of EBV in posttransplant malignancies: A review
58. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders
59. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children
60. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease
61. CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab
62. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
63. Human herpesvirus-6 and human herpesvirus-7 in the bone marrow from healthy subjects
64. Herpesvirus type 6 in patients undergoing bone marrow transplantation: Serologic features and detection by polymerase chain reaction
65. Brief report: Fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient
66. Human herpesvirus-6 meningoencephalitis in a recipient of an unrelated allogeneic bone marrow transplantation
67. Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients
68. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation
69. Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation
70. Human herpesvirus 6 infections after bone marrow transplantation: Clinical and virologic manifestations
71. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): Epidemiology and pathogenesis
72. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients
73. Kaposi's sarcoma after allogeneic bone marrow transplantation in a child